Potent antimalarial activity of histone deacetylase inhibitor analogues

K. T. Andrews, T. N. Tran, A. J. Lucke, P. Kahnberg, G. T. Le, G. M. Boyle, D. L. Gardiner, T. S. Skinner-Adams, D. P. Fairlie

Research output: Contribution to journalArticleResearchpeer-review

92 Citations (Scopus)

Abstract

The malaria parasite Plasmodium falciparum has at least five putative histone deacetylase (HDAC) enzymes, which have been proposed as new antimalarial drug targets and may play roles in regulating gene transcription, like the better-known and more intensively studied human HDACs (hHDACs). Fourteen new compounds derived from L-cysteine or 2-aminosuberic acid were designed to inhibit P. falciparum HDAC-1 (PfHDAC-1) based on homology modeling with human class I and class II HDAC enzymes. The compounds displayed highly potent antiproliferative activity against drug-resistant (Dd2) or drug sensitive (3D7) strains of P. falciparum in vitro (50% inhibitory concentration of 13 to 334 nM). Unlike known hHDAC inhibitors, some of these new compounds were significantly more toxic to P. falciparum parasites than to mammalian cells. The compounds inhibited P. falciparum growth in erythrocytes at both the early and late stages of the parasite's life cycle and caused altered histone acetylation patterns (hyperacetylation), which is a marker of HDAC inhibition in mammalian cells. These results support PfHDAC enzymes as being promising targets for new antimalarial drugs.

Original languageEnglish
Pages (from-to)1454-1461
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume52
Issue number4
DOIs
Publication statusPublished - 1 Apr 2008
Externally publishedYes

Cite this